000126556 001__ 126556
000126556 005__ 20240228140832.0
000126556 0247_ $$2doi$$a10.1200/JCO.2014.59.9217
000126556 0247_ $$2pmid$$apmid:26304884
000126556 0247_ $$2pmc$$apmc:PMC4567701
000126556 0247_ $$2ISSN$$a0732-183X
000126556 0247_ $$2ISSN$$a1527-7755
000126556 0247_ $$2altmetric$$aaltmetric:4433464
000126556 037__ $$aDKFZ-2017-02584
000126556 041__ $$aeng
000126556 082__ $$a050
000126556 1001_ $$aGajjar, Amar$$b0
000126556 245__ $$aPediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape.
000126556 260__ $$aAlexandria, Va.$$bAmerican Society of Clinical Oncology$$c2015
000126556 3367_ $$2DRIVER$$aarticle
000126556 3367_ $$2DataCite$$aOutput Types/Journal article
000126556 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1508414004_6998
000126556 3367_ $$2BibTeX$$aARTICLE
000126556 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000126556 3367_ $$00$$2EndNote$$aJournal Article
000126556 520__ $$aPediatric neuro-oncology has undergone an exciting and dramatic transformation during the past 5 years. This article summarizes data from collaborative group and institutional trials that have advanced the science of pediatric brain tumors and survival of patients with these tumors. Advanced genomic analysis of the entire spectrum of pediatric brain tumors has heralded an era in which stakeholders in the pediatric neuro-oncology community are being challenged to reconsider their current research and diagnostic and treatment strategies. The incorporation of this new information into the next-generation treatment protocols will unleash new challenges. This review succinctly summarizes the key advances in our understanding of the common pediatric brain tumors (ie, medulloblastoma, low- and high-grade gliomas, diffuse intrinsic pontine glioma, and ependymoma) and some selected rare tumors (ie, atypical teratoid/rhabdoid tumor and CNS primitive neuroectodermal tumor). The potential impact of this new information on future clinical protocols also is discussed. Cutting-edge genomics technologies and the information gained from such studies are facilitating the identification of molecularly defined subgroups within patients with particular pediatric brain tumors. The number of evaluable patients in each subgroup is small, particularly in the subgroups of rare diseases. Therefore, international collaboration will be crucial to draw meaningful conclusions about novel approaches to treating pediatric brain tumors.
000126556 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000126556 588__ $$aDataset connected to CrossRef, PubMed,
000126556 7001_ $$aBowers, Daniel C$$b1
000126556 7001_ $$aKarajannis, Matthias A$$b2
000126556 7001_ $$aLeary, Sarah$$b3
000126556 7001_ $$0P:(DE-He78)046fd145f1008f83f6236580727bbc0f$$aWitt, Hendrik$$b4$$udkfz
000126556 7001_ $$aGottardo, Nicholas G$$b5
000126556 773__ $$0PERI:(DE-600)2005181-5$$a10.1200/JCO.2014.59.9217$$gVol. 33, no. 27, p. 2986 - 2998$$n27$$p2986 - 2998$$tJournal of clinical oncology$$v33$$x1527-7755$$y2015
000126556 909CO $$ooai:inrepo02.dkfz.de:126556$$pVDB
000126556 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)046fd145f1008f83f6236580727bbc0f$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000126556 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000126556 9141_ $$y2015
000126556 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000126556 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CLIN ONCOL : 2015
000126556 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000126556 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000126556 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000126556 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000126556 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000126556 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000126556 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000126556 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000126556 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000126556 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bJ CLIN ONCOL : 2015
000126556 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000126556 980__ $$ajournal
000126556 980__ $$aVDB
000126556 980__ $$aI:(DE-He78)B062-20160331
000126556 980__ $$aUNRESTRICTED